β 淀粉样蛋白级联假说相关的阿尔茨海默病发病机制及防治策略研究进展
β Amyloid Hypothesis in Alzheimer's Disease: Pathogenesis, Prevention,and Management
查看参考文献56篇
|
文摘
|
阿尔茨海默病( AD)是一种以进行性认知功能障碍和记忆衰退为特点的中枢神经系统疾病。研究表明,β淀粉样蛋白( Aβ)是AD发生的关键环节,被认为是遗传因素和环境因素共同作用引发AD病程的上游分子。Aβ聚集及由此引发的细胞炎症反应等被认为是AD患者脑内提前于神经元变性的早期事件,但目前针对Aβ聚集这一环节的药物尚无一种通过临床3期试验,提示了AD发病过程的复杂性,也使Aβ级联假说面临挑战。本文总结了AD发病机制中的重要学说—Aβ级联假说及与其相关的AD病理、病理生理过程和治疗的研究进展。 |
|
其他语种文摘
|
Alzheimer's disease ( AD) is a central nervous system disease characterized by progressive cognitive dysfunction and memory loss. Increasing evidences suggest that β amyloid ( Aβ) plays a critical role and may be a upstream molecule in AD pathogenesis involving both genetic and environmental factors. Aβ accumulation and its related inflammation are considered early events preceding neurodegeneration and neuronal loss in AD brain. However,all strategies and compounds targeting Aβ deposition have failed in clinical trials,implying complexity of AD pathogenesis. This article reviews Aβ hypothesis and its related mechanisms,pathophysiological process,and therapeutics of AD. |
|
来源
|
中国医学科学院学报
,2019,41(5):702-708 【核心库】
|
|
DOI
|
10.3881/j.issn.1000-503x.10875
|
|
关键词
|
阿尔茨海默病
;
β 淀粉样蛋白
;
炎症反应
;
Tau蛋白
|
|
地址
|
首都医科大学基础医学院生理学与病理生理学系, 北京, 100069
|
|
语种
|
中文 |
|
文献类型
|
综述型 |
|
ISSN
|
1000-503X |
|
学科
|
神经病学与精神病学 |
|
文献收藏号
|
CSCD:6605978
|
参考文献 共
56
共3页
|
|
1.
Tokuchi R. Differences between the behavioral and psychological symptoms of Alzheimer's disease and Parkinson's disease.
J Neurol Sci,2016,369:278-282
|
CSCD被引
2
次
|
|
|
|
|
2.
Rabinovici G D. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
Alzheimers Dement,2016,12(4):510-515
|
CSCD被引
5
次
|
|
|
|
|
3.
Selkoe D J. The amyloid hypothesis of Alzheimer's disease at 25 years.
EMBO Mol Med,2016,8(6):595-608
|
CSCD被引
135
次
|
|
|
|
|
4.
Sharma S. Alzheimer's disease like pathology induced six weeks after aggregated amyloid-beta injection in rats: increased oxidative stress and impaired long-term memory with anxiety-like behavior.
Neurol Res,2016,38(9):838-850
|
CSCD被引
6
次
|
|
|
|
|
5.
Goedert M. Neurodegeneration. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ,tau, and α-synuclein.
Science,2015,349(6248):1255555
|
CSCD被引
30
次
|
|
|
|
|
6.
Pooler A M. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease.
Acta Neuropathol Commun,2015,3:14
|
CSCD被引
6
次
|
|
|
|
|
7.
Minjarez B. Identification of proteins that are differentially expressed in brains with Alzheimer's disease using iTRAQ labeling and tandem mass spectrometry.
J Proteomics,2016,139:103-121
|
CSCD被引
1
次
|
|
|
|
|
8.
Tycko R. Alzheimer's disease: Structure of aggregates revealed.
Nature,2016,537(7621):492-493
|
CSCD被引
3
次
|
|
|
|
|
9.
Walsh D M. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.
Nature,2002,416(6880):535-539
|
CSCD被引
78
次
|
|
|
|
|
10.
Cleary J P. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function.
Nat Neurosci,2005,8(1):79-84
|
CSCD被引
33
次
|
|
|
|
|
11.
Grutzendler J. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer's disease.
Ann N Y Acad Sci,2010,1097(1):30-39
|
CSCD被引
2
次
|
|
|
|
|
12.
Tsai J. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches.
Nat Neurosci,2004,7(11):1181-1183
|
CSCD被引
6
次
|
|
|
|
|
13.
Shankar G M. Amyloid-[beta]protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.
Nat Med,2008,14(8):837-842
|
CSCD被引
72
次
|
|
|
|
|
14.
Shin M K. A novel brain-derived neurotrophic factor-modulating peptide attenuates Aβ1-42-induced neurotoxicity in vitro.
Neurosci Lett,2015,595:63-68
|
CSCD被引
2
次
|
|
|
|
|
15.
Bouter Y. Abeta targets of the biosimilar antibodies of Bapineuzumab,Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models.
Acta Neuropathol,2015,130(5):713-729
|
CSCD被引
4
次
|
|
|
|
|
16.
Bohrmann B. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.
J Alzheimers Dis,2012,28(1):49-69
|
CSCD被引
3
次
|
|
|
|
|
17.
Shi Q. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice.
Sci Transl Med,2017,9(392)
|
CSCD被引
1
次
|
|
|
|
|
18.
Bachhuber T. Inhibition of amyloid-β plaque formation by α-synuclein.
Nat Med,2015,21(7):802-807
|
CSCD被引
3
次
|
|
|
|
|
19.
Szekely C A. NSAIDs for the chemoprevention of Alzheimer's disease.
Subcell Biochem,2007,42:229-248
|
CSCD被引
4
次
|
|
|
|
|
20.
Cole G M. NSAIDs and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models.
Ann N Y Acad Sci,2010,1035(1):68-84
|
CSCD被引
4
次
|
|
|
|
|
了解气象卫星更多信息，请访问